drugset / Trial / NCT00363519

Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus

NCT00363519

Phase 3 Completed 195 enrolled Ono Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of MK-0431/ONO-5435 in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and glimepiride as monotherapy

Timeline

Start
2006-08
Primary completion
2008-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Sitagliptin Small molecule 100 mg